Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Verto Homes have created the Zero Carbon Smart Home. These homes create and store their own clean energy from the sun, they automatically know when and where light heat and shade are needed and they manage the energy they use so efficiently that their energy bills are almost 0.
days to go:
Expired
investment:
£1,389,280
AgeWage is a pension scoring system that provides customized information to the customers. By bringing together your pension pots, AgeWage scores each of the pension pot out of 100 and tells you how well they have worked for you. The scoring system offers information that helps the customer make decisions on how to consolidate pots, reinvest their money and most importantly, how to get their money back. The company has signed an MoU with Royal London to enter into B2B arrangements. It was also chosen for the Direct Support Innovate programme with the FCA. AgeWage has been voted the best new idea in the BGL partnership awards(2018). With its proceeds, the company is planning to invest in digital development, marketing the application to the general public and other organizations. Also, it is trying to build out the infrastructure to support the development of the product with third parties such as Annuity Providers, IFAs, and Drawdown Providers.
days to go:
Expired
investment:
£317,760
Lenderwize are a SEIS approved, UK based Crowdlending platform for Telcos. They seek to bridge the cash flow gap for telecom operators which sell to big operators and must pay their vendors upfront whilst waiting for their own clients to pay them. Lenderwize currently has a working platform with over £5,000,000 in requests from borrowers and over £9,000,000 from institutional investors.
days to go:
Expired
investment:
£78,076
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.
days to go:
Expired
investment:
£142,026
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. ABBS asserts that mines and IEDs accounted for over 80% of UK and US army casualties in Iraq and Afghanistan. ABBS aims to change this and become a major contender in the $20 billion armoured vehicle protection market. The company points out that it has been tasked by the European Union Aviation Safety Agency (EASA) and European Organisation for Civil Aviation Equipment (EUROCAE) to draft safety regulations for emergency descent arrest systems. The company also holds multiple patents for its proven Vehicle Global Acceleration Mitigation (VGAM) vehicle mine protection system and has a patent pending for a Zero-Zero Crash Prevention (ZZCP) system for light aircraft and electric Vertical Takeoff and Landing (eVTOLs) systems. It will use the investment for marketing, boosting R&D, and maintaining and expanding its IP/patent portfolio.
days to go:
Expired
investment:
£88,003
